Financial reports
10-K
2023 FY
Annual report
8 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
28 Jul 23
10-Q
2023 Q1
Quarterly report
3 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
10-K
2022 FY
Annual report
9 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
24 Feb 22
Current reports
8-K
Entry into a Material Definitive Agreement
17 Apr 24
8-K
Vanda Pharmaceuticals’ Fanapt® (iloperidone) Receives U.S. FDA Approval
3 Apr 24
8-K
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
7 Mar 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
8-K/A
Special Purpose Abbreviated Financial Statements
16 Feb 24
8-K
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7 Feb 24
8-K
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
5 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Dec 23
8-K
Entry into a Material Definitive Agreement
7 Dec 23
8-K
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
8 Nov 23
Registration and prospectus
8-A12B
Registration of securities on exchange
17 Apr 24
S-8
Registration of securities for employees
8 Jun 23
S-3/A
Shelf registration (amended)
3 May 23
S-3
Shelf registration
9 Feb 23
S-8
Registration of securities for employees
17 Jun 22
S-8
Registration of securities for employees
10 Jun 21
S-8
Registration of securities for employees
11 Jun 20
S-8
Registration of securities for employees
13 Jun 18
424B5
Prospectus supplement for primary offering
16 Mar 18
424B5
Prospectus supplement for primary offering
14 Mar 18
Proxies
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEFA14A
Additional proxy soliciting materials
26 May 20
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
DEFA14A
Additional proxy soliciting materials
25 Apr 19
Other
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
3 May 23
UPLOAD
Letter from SEC
16 Feb 23
CT ORDER
Confidential treatment order
24 Apr 20
CT ORDER
Confidential treatment order
26 Jun 17
CT ORDER
Confidential treatment order
4 May 17
CT ORDER
Confidential treatment order
4 Oct 16
EFFECT
Notice of effectiveness
21 Jul 15
CORRESP
Correspondence with SEC
17 Jul 15
UPLOAD
Letter from SEC
16 Jul 15
Ownership
4
Timothy Williams
6 Mar 24
4
Joakim Wijkstrom
6 Mar 24
4
Mihael Hristos Polymeropoulos
6 Mar 24
4
Kevin Patrick Moran
6 Mar 24
4
Gunther Birznieks
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24